Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maribavir Treatment of Cytomegalovirus for Lymphoid Malignancy Patients Undergoing Bispecific Antibodies

NCT07014319 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT07014319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maribavir Treatment of Cytomegalovirus for Lymphoid Malignancy Patients Undergoing Bispecific Antibodies
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 3, 2025
Completion date
January 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv)